Alogliptin for the treatment of Type 2 diabetes

References

• International Diabetes Federation. IDF Diabetes Atlas, 6th edition. International Diabetes Federation; Brussels, Belgium: 2013
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12
   PubMed Web of Science ®Google Scholar
• Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: a questionnaire survey of 18,385 diabetics over a 10-year period. J Diabetes Invest 2010;1(1-2):66-76
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56(4):696-708
   PubMed Web of Science ®Google Scholar
• Fukushima M, Aoyama S, Taniguchi A, Seino Y. Cliical characteristics of Asian diabetics: in view of insulin secretory defect and insulin resistance. J Diabetes Invest 2012;3(Suppl 1):54
   Google Scholar
• Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004;66(Suppl 1):S37-43
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan 2013. Japan Diabetes Society; Japan: 2013
   Google Scholar
• Garber AJ. Incretin therapy–present and future. Rev Diabet Stud 2011;8(3):307-22
   PubMedGoogle Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013;4(2):108-30
   PubMed Web of Science ®Google Scholar
• Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Health Patient Safe 2010;2:7-19
   PubMedGoogle Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50(10):2297-300
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008;588(2-3):325-32
   PubMed Web of Science ®Google Scholar
• Lee B, Shi L, Kassel DB, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008;589(1-3):306-14
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30(3):513-27
   PubMed Web of Science ®Google Scholar
• Hirayam M, Matsuno K, Fujita T, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Abstract 521-P Diabetes 2008;57(Suppl 1):A155
   Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30(3):499-512
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33(2):187-215
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013;10(2):73-84
   PubMed Web of Science ®Google Scholar
• Ta NN, Li Y, Schuyler CA, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010;213:429-35
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-49
   PubMed Web of Science ®Google Scholar
• Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;58:157-66
   PubMed Web of Science ®Google Scholar
• Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013;12:8
   PubMed Web of Science ®Google Scholar
• Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010;48(1):46-58
   PubMed Web of Science ®Google Scholar
• Vipidia (alogliptin) 6.25mg, 12.5mg, 25mg film-coated tablets: summary of product characteristics. Takeda UK Ltd, High Wycombe, UK 2014
   Google Scholar
• Karim A, Fleck P, Harrell RE, et al. Effects of age, race and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor in healthy subjects [abstract PI-14]. Clin Pharmacol Ther 2008;83:Suppl:S13
   Google Scholar
• Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract 538-P]. Diabetes 2008;57(Suppl 1)):A160
   Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31(12):2315-17
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011;27(9):1781-92
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010;33(11):2406-8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63(1):46-55
   PubMed Web of Science ®Google Scholar
• Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012;14(10):927-36
   PubMed Web of Science ®Google Scholar
• Pratley RE, Reusch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25(10):2361-71
   PubMed Web of Science ®Google Scholar
• Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 2011;13(11):1028-35
   PubMed Web of Science ®Google Scholar
• Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11(2):167-76
   PubMed Web of Science ®Google Scholar
• Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Invest 2012;3(6):517-25
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;3:21-9
   Google Scholar
• Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11(12):1145-52
   PubMed Web of Science ®Google Scholar
• Kaku K, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Expert Opin Pharmacother 2014; In press
   Web of Science ®Google Scholar
• Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;15(10):906-14
   PubMed Web of Science ®Google Scholar
• Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009;57(11):2011-19
   PubMed Web of Science ®Google Scholar
• Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin [poster 66-LB]. 73rd Scientific Sessions of the American Diabetes Association; Chicago, USA: 2013
   Google Scholar
• European Medicines Agency. CHMP assessment report: Vipidia (EMA/CHMP/207780/2013). European Medicines Agency; London, UK: 2013
   Google Scholar
• Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord 2013;13:9
   PubMed Web of Science ®Google Scholar
• Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy–focus on alogliptin. Drug Des Devel Ther 2013;7:989-1001
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10(4):289-301
   PubMed Web of Science ®Google Scholar
• Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157(9):601-10
   PubMed Web of Science ®Google Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15(10):938-53
   PubMed Web of Science ®Google Scholar
• White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013;15(7):668-73
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369(14):1327-35
   PubMed Web of Science ®Google Scholar
• Gupta V, Kalra S. Choosing a gliptin. Ind J Endocrinol Metab 2011;15(4):298-308
   PubMedGoogle Scholar
• Trajenta (linagliptin) 5 mg film-coated tablets: summary of product characteristics. Boehringer Ingelheim Limited; Bracknell, UK: 2013
   Google Scholar
• Onglyza (saxagliptin) 2.5mg & 5mg film-coated tablets: summary of product characteristics. Bristol Myers Squibb-AstraZeneca EEIG; Uxbridge, UK: 2014
   Google Scholar
• Januvia (sitagliptin) 25mg, 50mg, 100mg film-coated tablets: summary of product characteristics. Merck Sharp & Dohme Limited; Hoddesdon, UK: 2013
   Google Scholar
• Galvus (vildagliptin) 50mg tablets: summary of product characteristics. Novartis Pharmaceuticals UK Ltd; Camberley, UK: 2014
   Google Scholar
• Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther 2014;5(1):1-41
   PubMed Web of Science ®Google Scholar
• Messori A, Fadda V, Maratea D, et al. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes. Diabetes Ther 2014;5(1):341-4
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573-88
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. “Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?” J Diabetes Investig Article first published online 2014; DOI: 10.1111/jdi.12229
   Web of Science ®Google Scholar
• Plantinga LC, Crews DC, Coresh J, et al. CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010;5(4):673-82
   PubMed Web of Science ®Google Scholar
• Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther 2013;30(12):1067-85
   PubMed Web of Science ®Google Scholar
• Sakai Y, Suzuki A, Mugishima K, et al. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. Intern Med 2014;53(3):195-203
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010;1(1-2):56-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Watanabe K, Suguwara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Invest 2012;3(1):70-9
   PubMed Web of Science ®Google Scholar
• Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013;97(3):505-16
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Hoshian F, Tsuji T, et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest 2012;3:464-7
   PubMed Web of Science ®Google Scholar
• Senmaru T, Fukui M, Kobayashi K, et al. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Investig 2012;3:498-502
   PubMed Web of Science ®Google Scholar
• Aulinger BA, Bedorf A, Kutscherauer G, et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 2014;63:1079-92
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003;88:4897-903
   PubMed Web of Science ®Google Scholar
• Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199-207
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Carneiro L, Derani A, et al. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 2012;61:2349-58
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 2014;5(3):138-46
   PubMedGoogle Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150-6
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173(7):534-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuwata H, Kaneko M, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral anti-diabetic drugs. Diabetes Obes Metab 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33(11):2349-54
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16(1):48-56
   PubMed Web of Science ®Google Scholar
• Torekov SS, Harsløf T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014;99:E729-33
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34(11):2474-6
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control. J Diabetes Investig 2012;3(4):347-8
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010;1(1-2):8-23
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56(4):728-33
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33(7):1607-9
   PubMed Web of Science ®Google Scholar
• Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62(3):347-51
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26
   PubMed Web of Science ®Google Scholar
• Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12:3
   PubMed Web of Science ®Google Scholar
• Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15(2):112-20
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Yoshii H, et al. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). J Atheroscler Thromb 2013;20(12):893-902
   PubMed Web of Science ®Google Scholar